Tcr2 Therapeutics Inc

Tcr2 Therapeutics — Technical Presentation (July 2020)

27 slides from Tcr2 Therapeutics's technical presentation, Jul 27, 2020

  1. Slide 1: Presentation of Clinical Data from First Cohort of TC-210 Patients

    Exhibit 99.2 Presentation of Clinical Data from First Cohort of TC-210 Patients Trial ongoing with additional patients enrolled and treatedExhibit 99.2 Presentation of Clinical Data from First Cohort of TC-210 Patients Trial ongoing with additional patients enrolled and treated

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements 2 This presentation has been prepared by TCR Therapeutics Inc. (“we,” “us,” or planned Phase 1 clinical trial of TC-110; the risk that the results from the Phase “our”) and contains forward-looking statements within the meaning of the Private 1/2 clinical trial of TC-210 w

  3. Slide 3: Introduction

    Introduction Garry Menzel, PhD Chief Executive Officer 3Introduction Garry Menzel, PhD Chief Executive Officer 3

  4. Slide 4: Key Takeaways from Our First Cohort of TC-210 Patients

    Key Takeaways from Our First Cohort of TC-210 Patients Clinical Trial Overview Key Clinical Findings § Data on first 5 patients: 4 patients with § Screening: 48% patients eligible mesothelioma, 1 with ovarian cancer § Manufacturing: 100% success rate § Single infusion of TC-210 TRuC-T Cells § Safety

  5. Slide 5: Mesothelin Is an Excellent Solid Tumor Target

    Mesothelin Is an Excellent Solid Tumor Target Mesothelin is highly expressed on tumors Expression Lower expression in normal tissue, No expression Patterns confined to mesothelium in pleura, in vital organs peritoneum and pericardium Target validation from competitor programs, including: Clinical Da

  6. Slide 6: Mesothelin Solid Tumors Represent A Significant Market

    Mesothelin Solid Tumors Represent A Significant Market Malignant Pleural Cholangiocarcinoma Ovarian Cancer NSCLC Mesothelioma 76% 50% 58% 31% 2,100 4,000 13,000 61,000 Market Opportunity: Market Opportunity: Market Opportunity: Market Opportunity: ~$700M ~$800M ~$1.6B ~$1.6B Fast Track Potential Per

  7. Slide 7: TC-210 Clinical Trial Review

    TC-210 Clinical Trial Review Alfonso Quintás-Cardama, MD Chief Medical Officer 7TC-210 Clinical Trial Review Alfonso Quintás-Cardama, MD Chief Medical Officer 7

  8. Slide 8: Ongoing TC-210 Phase 1/2 Trial in MSLN+ Cancers

    Ongoing TC-210 Phase 1/2 Trial in MSLN+ Cancers PHASE 1: Dose Finding PHASE 2: Expansion NSCLC NSCLC 4 n=8 n=12 Dose Level 7 (+ LD) + anti-PD1 Dose Level 6 (- LD) 3 Ovarian Cancer Dose Level 5 (+ LD) n=10 Dose Level 4 (- LD) RP2D 2 Cholangiocarcinoma Dose Level 3 (+ LD) n=10 Dose Level 2 (- LD) Indi

  9. Slide 9: Enrollment Rules During Phase 1

    Enrollment Rules During Phase 1 Modified 3+3 Dose Escalation 7 2 5x10 TC-210 T Cells/m >28 Days >28 Days >28 Days 1 Patient First Dose 1 Patient 1 Patient Second Dose 1 Patient Dose Level 1 Dose Level 0 (No LD) (With LD) 9 LD: LymphodepletionEnrollment Rules During Phase 1 Modified 3+3 Dose Escalati

  10. Slide 10: TC-210 Study: Patient Flow

    TC-210 Study: Patient Flow MSLN Pre-Screen Apheresis TC-210 Infusion LTFU TC-210 Manufacture 1 2 3 6 12 24 Safety and Efficacy Monitoring Screening Mesothelin Expression Lymphodepletion Regimen Clinical Trial Sites 2 § Central lab (Roche/Ventana)§ Fludarabine (F): 30 mg/m x4§ Sarah Cannon Research I

  11. Slide 11: TC-210 Phase 1 Dose Escalation: Objectives

    TC-210 Phase 1 Dose Escalation: Objectives Primary Exploratory § Expansion, persistence, phenotype, § Safety (Establish the RP2D) functionality of TC-210 T-cells § Serum cytokine levels § Immunogenicity Secondary § ORR (CR + PR) according to RECIST v1.1 § DCR (ORR + SD) § Duration of response § Surv

  12. Slide 12: TC-210 Phase 1 Dose Escalation: Eligibility Criteria

    TC-210 Phase 1 Dose Escalation: Eligibility Criteria Key Inclusion Criteria § ≥ 18 years of age § Adequate Performance Status and organ function § Pathologically confirmed MPM, NSCLC, ovarian cancer, or cholangiocarcinoma § Must have received at least 1 systemic standard of care therapy for metastat

  13. Slide 13: Pre-Screening, Enrollment and Manufacturing Activity

    Pre-Screening, Enrollment and Manufacturing Activity Patients Pre-Screened 79 § MSLN expression above enrollment cutoff in ~50% of screened patients Tumor Samples 62 Resulted § Products meeting protocol specifications have been successfully MSLN 2+/3+ in ≥ 50% viable tumor cells 30 (48) manufactured

  14. Slide 14: Patient Characteristics

    Patient Characteristics Characteristics N = 5 Median age, years (range) 61 (36-74) Cancer diagnosis Mesothelioma 4 (2 peritoneal, 2 pleural) Ovarian cancer 1 Median No. of prior therapies (range) 5 (3-9) ≥4 prior therapies, No. (%) 3 (60) Prior ICI therapy, No. (%) 3 (60) Prior anti-MSLN directed th

  15. Slide 15: Summary of Grade ≥3 Treatment Emergent Adverse Events

    Summary of Grade ≥3 Treatment Emergent Adverse Events Adverse Event N = 5 (%) Hematologic Neutropenia 4 (80) Lymphopenia 5 (100) Thrombocytopenia 1 (20) Adverse Events of Special Interest On Target / On Tumor CRS* 1 (20) Neurotoxicity 0 On Target / Off Tumor Pericarditis / Pericardial effusion 0 Ple

  16. Slide 16: RECIST v1.1 Response Assessment Summary

    RECIST v1.1 Response Assessment Summary Patients 1 2 3 4 5 Age/Sex 61/M 74/M 52/F 36/M 70/F Diagnosis MPM MPM MPM MPM Ovarian Ca MSLN 2+/3+ 90 60 73 95 55 (% of tumor cells) No. Prior Rx 8** 3 3 9 6 Pemetrexed/ Pemetrexed/ Liposomal Bridging Therapy None None Cisplatin Carboplatin doxorubicin LD Che

  17. Slide 17: Tumor Regression Observed in All Patients with TC-210

    Tumor Regression Observed in All Patients with TC-210 Overall Response Rate 40%, Disease Control Rate 100% 30 20 10 0 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 -10 -20 -17 -20 -30 -40 -42 -50 -60 ** -64 -70 -67 -80 -90 -100 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 17 ** New Lesion a

  18. Slide 18: Early Efficacy Case Study: Patient 2

    Early Efficacy Case Study: Patient 2 Partial Response (RECIST v1.1), Significant Tumor Regression (67%), Complete Metabolic Response 74-year-old male, epithelioid pleural mesothelioma Baseline Week 3 3 3 31mm, 8.5cm 15mm, 1.3cm § Extensive surgery Feb 2018 PD § Pembrolizumab Sep 2018 PD § Carboplati

  19. Slide 19: Early Efficacy Case Study: Patient 2

    Early Efficacy Case Study: Patient 2 74-year-old male, epithelioid pleural mesothelioma Baseline Week 3 (PET Scan) (PET Scan) Soluble Mesothelin & MPF Complete Metabolic Response 19 Target Lesion 2Early Efficacy Case Study: Patient 2 74-year-old male, epithelioid pleural mesothelioma Baseline Week 3

  20. Slide 20: Early Efficacy Case Study: Patient 3

    Early Efficacy Case Study: Patient 3 Significant Tumor Regression (64%) Baseline Week 12 Week 24 52-year-old female, epithelioid mesothelioma 3 3 3 33mm, 12.9cm 25mm, 8.3cm 12mm, 1.2cm § Diagnosed Aug 2015 § Left parietal pleurectomy § Cisplatin/pemetrexed Oct 2015 SD § Extensive cervical, mediastin

  21. Slide 21: Patient Response and Follow-Up

    Patient Response and Follow-Up Overall Response Rate 40%, Disease Control Rate 100% 001 - MPM 002 - MPM No LD LD 003 - MPM SD PR 004 - MPM PD Alive Death 005 - OvCa 0 1 2 3 4 5 6 7 8 9 Time (Months) 21 PatientsPatient Response and Follow-Up Overall Response Rate 40%, Disease Control Rate 100% 001 -

  22. Slide 22: TC-210 T Cell Expansion in Peripheral Blood by qPCR

    TC-210 T Cell Expansion in Peripheral Blood by qPCR TC-210 Kinetics Peak of TC-210 Expansion § Expansion of TC-210 T Cells in peripheral blood observed in all patients § Peak expansion occurred between days 7-22 post infusion § Highest expansion was observed among patients receiving lymphodepletion

  23. Slide 23: Cytokine Levels in Peripheral Blood Following TC-210 Infusion

    Cytokine Levels in Peripheral Blood Following TC-210 Infusion IFN IL-10 IL-12 Patient 1 Patient 2 Patient 3 Patient 4 IL-6 IL-8 TNF〈 Patient 5 Infusion § TC-210 infusion increased cytokine levels in peripheral blood in all patients § Higher levels were observed in Patient 2, who experienced grade 3

  24. Slide 24: TC-210: Summary and Future Direction

    TC-210: Summary and Future Direction § Encouraging data at first dose tested o Consistent clinical benefit at first TC-210 T cell dose o Manageable safety profile o High rate of patient eligibility and 100% manufacturing success § Next steps o Continue dose escalation until identification of RP2D o

  25. Slide 25: 2020 Company Milestones

    2020 Company Milestones 2H20 2H20 TC-210 TC-110 Phase 1 Follow-Up Update Phase 1 Interim Update Target: Mesothelin Target: CD19 Indications: Ovarian Cancer, NSCLC, MPM, Cholangiocarcinoma Indications: aALL, DLBCL, NHL Endpoints: Safety, Efficacy & Translational Data Endpoints: Safety, Efficacy & Tra

  26. Slide 26: Early Clinical Validation of TRuC-T Cell Platform

    Early Clinical Validation of TRuC-T Cell Platform Strengths Increased TRAFFICKING Faster T-Cell Homing Migration Receptors CONTROL TARGETING Reduced Preferential Cytokine Killing Release Long-Lasting Enhanced MICRO- Anti-Tumor PERSISTENCE Metabolism ENVIRONMENT Activity 26Early Clinical Validation o

  27. Slide 27: Powering T Cells for Cancer Cures

    &. TCR’ POWERING T CELLS FOR CANCER CURES

TCR2 Therapeutics — Technical Presentation (July 2020) on 6ix